Ann: Renounceable Rights Issue, page-9

Summary of the Announcement - Rights Issue by Biotron Limited

Key Details:

• Rights Issue Type: 1-for-1 renounceable rights issue.
• Amount to be Raised: Up to $2.7 million.
• Price per Share:0.3 cents (66% discount to last price of 0.9 cents, 70% discount to 30-day VWAP of 1 cent).
• Rights Trading Start Date:5 March 2025.
• Closing Date:19 March 2025.
• Partial Underwriting:$750,000 underwritten by Mahe Capital.
• Directors’ Participation: All directors intend to take up their full entitlements.

Use of Funds:

1. Strategic Partnerships: Continue working with US-based C14 Consulting Group LLC to secure partnerships for Biotron’s antiviral programs, including BIT225.
2. Hepatitis B Research: Conduct a small animal study for Biotron’s Hepatitis B (HBV) compound.
3. Patent Portfolio Expansion: Maintain existing patents and support new patent filings progressing to International PCT applications.
4. Working Capital & Offer Costs: Ensure financial stability while pursuing commercialization opportunities.

Additional Notes:

• The rights issue replaces the previously announced share purchase plan (SPP) on 21 February 2025, which is now withdrawn.
• Shareholders with an Australian or New Zealand registered address are eligible to participate.
• Key Dates:
  • Prospectus lodgment: 3 March 2025
  • Rights trading ends: 12 March 2025
  • Results announced & shares issued: 26 March 2025